{"analyses":[{"ciLowerLimit":"0.773","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.206","estimateComment":"A HR of \\<1 favours fulvestrant.","groupDescription":"65% OS maturity","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.7579","pValueComment":"2-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.966","statisticalComment":"Stratified log-rank test with factors for prior chemotherapy for locally advanced or metastatic disease and measurable disease at baseline.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3"},{"groupId":"OG001","value":"67.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"OS was defined as the time from randomisation until death by any cause. The current OS data correspond to that of the final analysis and the outcome measure is reported as percentage of patients with events.","groups":[{"description":"Patients received fulvestrant (Faslodex™) 500 mg, administered as two 5 mL intramuscular injections, 1 in each buttock, at each visit on Days 0, 14 (±3), 28 (±3) and every 28 (±3) days thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive fulvestrant, also received placebo to match the anastrozole schedule (tablets, once daily).","id":"OG000","title":"Fulvestrant 500 mg"},{"description":"Patients received anastrozole (Arimidex™), administered orally as a single tablet at a dose of 1 mg/day from randomisation on Day 0 and once daily thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive anastrozole also received placebo to match the fulvestrant schedule (injections on Days 0, 14 \\[±3\\], 28 \\[±3\\] and every 28 \\[±3\\] days thereafter).","id":"OG001","title":"Anastrozole 1 mg"}],"paramType":"NUMBER","populationDescription":"The ITT analysis set included all randomised patients. Date of death of 2 participants were unknown in the Anastrozole 1mg arm, hence they were censored for OS analysis.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0) up to data cut-off for final analysis (up to approximately 116 months). Following disease progression, patients were to be contacted at 12 weekly intervals to determine survival status","title":"Comparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}